2 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 2 of 2 clinical reviews.
A detailed analysis of the BEGONIA trial's enrollment biases, follow-up gaps, statistical caveats, and conflict-of-interest issues that shaped the FDA approval of flibanserin (Addyi) for HSDD.
A deep-dive into the BEGONIA trial's real-world clinical implications for flibanserin (Addyi) prescribing in HSDD, including guideline updates, prescribing shifts, and patient selection beyond the trial population.
LegitScript certification
Verify HealthRX.comHealthRX.com is a platform connecting patients with independent licensed healthcare providers and pharmacies. Those providers deliver medical care and pharmacies dispense medication. Prescriptions are issued only when clinically appropriate. Payment does not guarantee a prescription.
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Individual results vary.
Website information is educational and is not a substitute for personalized medical advice, diagnosis, or treatment. Consult your licensed healthcare provider.